 | • レポートコード：QYR2104Z3545 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、132ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、悪性中皮腫治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他）、用途別市場規模（病院薬局、小売薬局、腫瘍センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・悪性中皮腫治療薬の市場動向 ・企業の競争状況、市場シェア ・悪性中皮腫治療薬の種類別市場規模（ペメトレキセド、シスプラチン、カルボプラチン、ゲムシタビン、ビノレルビン、その他） ・悪性中皮腫治療薬の用途別市場規模（病院薬局、小売薬局、腫瘍センター、その他） ・悪性中皮腫治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・悪性中皮腫治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・悪性中皮腫治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・悪性中皮腫治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・悪性中皮腫治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca、Bristol-Myers Squibb、Roche、Merck、Novartis、Pfizer、Sanofi、Eli Lilly、Teva Pharmaceuticals、Boehringer Ingelheim GmbH、Mylan、Fresenius Kabi、Sun Pharmaceuticals、Corden Pharma、Concordia International、Kyowa Hakko Kirin、Polaris Pharmaceuticals、MolMed、Ono Pharmaceutical、Nichi-Iko Pharmaceutical） ・結論 |
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.
Market Analysis and Insights: Global Malignant Mesothelioma Drugs Market
The global Malignant Mesothelioma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Mesothelioma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Mesothelioma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Mesothelioma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Mesothelioma Drugs market.
Global Malignant Mesothelioma Drugs Scope and Market Size
Malignant Mesothelioma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Mesothelioma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Oncology Centers
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AstraZeneca
Bristol-Myers Squibb
Roche
Merck
Novartis
Pfizer
Sanofi
Eli Lilly
Teva Pharmaceuticals
Merck
Novartis
Fresenius Kabi
Sun Pharmaceuticals
Corden Pharma
Concordia International
Kyowa Hakko Kirin
Polaris Pharmaceuticals
MolMed
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Carboplatin
1.2.5 Gemcitabine
1.2.6 Vinorelbine
1.2.7 Other
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Oncology Centers
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Drugs Market Perspective (2016-2027)
2.2 Malignant Mesothelioma Drugs Growth Trends by Regions
2.2.1 Malignant Mesothelioma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Malignant Mesothelioma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Malignant Mesothelioma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Malignant Mesothelioma Drugs Industry Dynamic
2.3.1 Malignant Mesothelioma Drugs Market Trends
2.3.2 Malignant Mesothelioma Drugs Market Drivers
2.3.3 Malignant Mesothelioma Drugs Market Challenges
2.3.4 Malignant Mesothelioma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Drugs Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Drugs Players by Revenue (2016-2021)
3.1.2 Global Malignant Mesothelioma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Malignant Mesothelioma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Mesothelioma Drugs Revenue
3.4 Global Malignant Mesothelioma Drugs Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Drugs Revenue in 2020
3.5 Malignant Mesothelioma Drugs Key Players Head office and Area Served
3.6 Key Players Malignant Mesothelioma Drugs Product Solution and Service
3.7 Date of Enter into Malignant Mesothelioma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Drugs Breakdown Data by Type
4.1 Global Malignant Mesothelioma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Malignant Mesothelioma Drugs Forecasted Market Size by Type (2022-2027)
5 Malignant Mesothelioma Drugs Breakdown Data by Application
5.1 Global Malignant Mesothelioma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Malignant Mesothelioma Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Malignant Mesothelioma Drugs Market Size (2016-2027)
6.2 North America Malignant Mesothelioma Drugs Market Size by Type
6.2.1 North America Malignant Mesothelioma Drugs Market Size by Type (2016-2021)
6.2.2 North America Malignant Mesothelioma Drugs Market Size by Type (2022-2027)
6.2.3 North America Malignant Mesothelioma Drugs Market Size by Type (2016-2027)
6.3 North America Malignant Mesothelioma Drugs Market Size by Application
6.3.1 North America Malignant Mesothelioma Drugs Market Size by Application (2016-2021)
6.3.2 North America Malignant Mesothelioma Drugs Market Size by Application (2022-2027)
6.3.3 North America Malignant Mesothelioma Drugs Market Size by Application (2016-2027)
6.4 North America Malignant Mesothelioma Drugs Market Size by Country
6.4.1 North America Malignant Mesothelioma Drugs Market Size by Country (2016-2021)
6.4.2 North America Malignant Mesothelioma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Drugs Market Size (2016-2027)
7.2 Europe Malignant Mesothelioma Drugs Market Size by Type
7.2.1 Europe Malignant Mesothelioma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Malignant Mesothelioma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Malignant Mesothelioma Drugs Market Size by Type (2016-2027)
7.3 Europe Malignant Mesothelioma Drugs Market Size by Application
7.3.1 Europe Malignant Mesothelioma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Malignant Mesothelioma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Malignant Mesothelioma Drugs Market Size by Application (2016-2027)
7.4 Europe Malignant Mesothelioma Drugs Market Size by Country
7.4.1 Europe Malignant Mesothelioma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Malignant Mesothelioma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type
8.2.1 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application
8.3.1 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Region
8.4.1 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Malignant Mesothelioma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Malignant Mesothelioma Drugs Market Size (2016-2027)
9.2 Latin America Malignant Mesothelioma Drugs Market Size by Type
9.2.1 Latin America Malignant Mesothelioma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Malignant Mesothelioma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Malignant Mesothelioma Drugs Market Size by Type (2016-2027)
9.3 Latin America Malignant Mesothelioma Drugs Market Size by Application
9.3.1 Latin America Malignant Mesothelioma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Malignant Mesothelioma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Malignant Mesothelioma Drugs Market Size by Application (2016-2027)
9.4 Latin America Malignant Mesothelioma Drugs Market Size by Country
9.4.1 Latin America Malignant Mesothelioma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Malignant Mesothelioma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type
10.2.1 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application
10.3.1 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Country
10.4.1 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Malignant Mesothelioma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Malignant Mesothelioma Drugs Introduction
11.1.4 AstraZeneca Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.1.5 AstraZeneca Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Malignant Mesothelioma Drugs Introduction
11.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Malignant Mesothelioma Drugs Introduction
11.3.4 Roche Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Malignant Mesothelioma Drugs Introduction
11.4.4 Merck Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Malignant Mesothelioma Drugs Introduction
11.5.4 Novartis Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Malignant Mesothelioma Drugs Introduction
11.6.4 Pfizer Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Malignant Mesothelioma Drugs Introduction
11.7.4 Sanofi Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.7.5 Sanofi Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Malignant Mesothelioma Drugs Introduction
11.8.4 Eli Lilly Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Details
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals Malignant Mesothelioma Drugs Introduction
11.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Boehringer Ingelheim GmbH
11.10.1 Boehringer Ingelheim GmbH Company Details
11.10.2 Boehringer Ingelheim GmbH Business Overview
11.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Introduction
11.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.10.5 Boehringer Ingelheim GmbH Recent Development
11.11 Mylan
11.11.1 Mylan Company Details
11.11.2 Mylan Business Overview
11.11.3 Mylan Malignant Mesothelioma Drugs Introduction
11.11.4 Mylan Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.11.5 Mylan Recent Development
11.12 Fresenius Kabi
11.12.1 Fresenius Kabi Company Details
11.12.2 Fresenius Kabi Business Overview
11.12.3 Fresenius Kabi Malignant Mesothelioma Drugs Introduction
11.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.12.5 Fresenius Kabi Recent Development
11.13 Sun Pharmaceuticals
11.13.1 Sun Pharmaceuticals Company Details
11.13.2 Sun Pharmaceuticals Business Overview
11.13.3 Sun Pharmaceuticals Malignant Mesothelioma Drugs Introduction
11.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.13.5 Sun Pharmaceuticals Recent Development
11.14 Corden Pharma
11.14.1 Corden Pharma Company Details
11.14.2 Corden Pharma Business Overview
11.14.3 Corden Pharma Malignant Mesothelioma Drugs Introduction
11.14.4 Corden Pharma Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.14.5 Corden Pharma Recent Development
11.15 Concordia International
11.15.1 Concordia International Company Details
11.15.2 Concordia International Business Overview
11.15.3 Concordia International Malignant Mesothelioma Drugs Introduction
11.15.4 Concordia International Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.15.5 Concordia International Recent Development
11.16 Kyowa Hakko Kirin
11.16.1 Kyowa Hakko Kirin Company Details
11.16.2 Kyowa Hakko Kirin Business Overview
11.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Drugs Introduction
11.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.16.5 Kyowa Hakko Kirin Recent Development
11.17 Polaris Pharmaceuticals
11.17.1 Polaris Pharmaceuticals Company Details
11.17.2 Polaris Pharmaceuticals Business Overview
11.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Drugs Introduction
11.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.17.5 Polaris Pharmaceuticals Recent Development
11.18 MolMed
11.18.1 MolMed Company Details
11.18.2 MolMed Business Overview
11.18.3 MolMed Malignant Mesothelioma Drugs Introduction
11.18.4 MolMed Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.18.5 MolMed Recent Development
11.18 Ono Pharmaceutical
.1 Ono Pharmaceutical Company Details
.2 Ono Pharmaceutical Business Overview
.3 Ono Pharmaceutical Malignant Mesothelioma Drugs Introduction
.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
.5 Ono Pharmaceutical Recent Development
11.20 Nichi-Iko Pharmaceutical
11.20.1 Nichi-Iko Pharmaceutical Company Details
11.20.2 Nichi-Iko Pharmaceutical Business Overview
11.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Introduction
11.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2016-2021)
11.20.5 Nichi-Iko Pharmaceutical Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Malignant Mesothelioma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Pemetrexed
Table 3. Key Players of Cisplatin
Table 4. Key Players of Carboplatin
Table 5. Key Players of Gemcitabine
Table 6. Key Players of Vinorelbine
Table 7. Key Players of Other
Table 8. Global Malignant Mesothelioma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Malignant Mesothelioma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Malignant Mesothelioma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Malignant Mesothelioma Drugs Market Share by Regions (2016-2021)
Table 12. Global Malignant Mesothelioma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Malignant Mesothelioma Drugs Market Share by Regions (2022-2027)
Table 14. Malignant Mesothelioma Drugs Market Trends
Table 15. Malignant Mesothelioma Drugs Market Drivers
Table 16. Malignant Mesothelioma Drugs Market Challenges
Table 17. Malignant Mesothelioma Drugs Market Restraints
Table 18. Global Malignant Mesothelioma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Malignant Mesothelioma Drugs Market Share by Players (2016-2021)
Table 20. Global Top Malignant Mesothelioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Drugs as of 2020)
Table 21. Ranking of Global Top Malignant Mesothelioma Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Malignant Mesothelioma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Malignant Mesothelioma Drugs Product Solution and Service
Table 25. Date of Enter into Malignant Mesothelioma Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Malignant Mesothelioma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Malignant Mesothelioma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Malignant Mesothelioma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Malignant Mesothelioma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Malignant Mesothelioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Malignant Mesothelioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Malignant Mesothelioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Malignant Mesothelioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Malignant Mesothelioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Malignant Mesothelioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Malignant Mesothelioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Malignant Mesothelioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Malignant Mesothelioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Malignant Mesothelioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Malignant Mesothelioma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Malignant Mesothelioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Malignant Mesothelioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Malignant Mesothelioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Malignant Mesothelioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Malignant Mesothelioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Malignant Mesothelioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. AstraZeneca Company Details
Table 66. AstraZeneca Business Overview
Table 67. AstraZeneca Malignant Mesothelioma Drugs Product
Table 68. AstraZeneca Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 69. AstraZeneca Recent Development
Table 70. Bristol-Myers Squibb Company Details
Table 71. Bristol-Myers Squibb Business Overview
Table 72. Bristol-Myers Squibb Malignant Mesothelioma Drugs Product
Table 73. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 74. Bristol-Myers Squibb Recent Development
Table 75. Roche Company Details
Table 76. Roche Business Overview
Table 77. Roche Malignant Mesothelioma Drugs Product
Table 78. Roche Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 79. Roche Recent Development
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Malignant Mesothelioma Drugs Product
Table 83. Merck Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 84. Merck Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Malignant Mesothelioma Drugs Product
Table 88. Novartis Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 89. Novartis Recent Development
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Malignant Mesothelioma Drugs Product
Table 93. Pfizer Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 94. Pfizer Recent Development
Table 95. Sanofi Company Details
Table 96. Sanofi Business Overview
Table 97. Sanofi Malignant Mesothelioma Drugs Product
Table 98. Sanofi Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 99. Sanofi Recent Development
Table 100. Eli Lilly Company Details
Table 101. Eli Lilly Business Overview
Table 102. Eli Lilly Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 103. Eli Lilly Recent Development
Table 104. Teva Pharmaceuticals Company Details
Table 105. Teva Pharmaceuticals Business Overview
Table 106. Teva Pharmaceuticals Malignant Mesothelioma Drugs Product
Table 107. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 108. Teva Pharmaceuticals Recent Development
Table 109. Boehringer Ingelheim GmbH Company Details
Table 110. Boehringer Ingelheim GmbH Business Overview
Table 111. Boehringer Ingelheim GmbH Malignant Mesothelioma Drugs Product
Table 112. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 113. Boehringer Ingelheim GmbH Recent Development
Table 114. Mylan Company Details
Table 115. Mylan Business Overview
Table 116. Mylan Malignant Mesothelioma Drugs Product
Table 117. Mylan Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 118. Mylan Recent Development
Table 119. Fresenius Kabi Company Details
Table 120. Fresenius Kabi Business Overview
Table 121. Fresenius Kabi Malignant Mesothelioma Drugs Product
Table 122. Fresenius Kabi Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 123. Fresenius Kabi Recent Development
Table 124. Sun Pharmaceuticals Company Details
Table 125. Sun Pharmaceuticals Business Overview
Table 126. Sun Pharmaceuticals Malignant Mesothelioma Drugs Product
Table 127. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 128. Sun Pharmaceuticals Recent Development
Table 129. Corden Pharma Company Details
Table 130. Corden Pharma Business Overview
Table 131. Corden Pharma Malignant Mesothelioma Drugs Product
Table 132. Corden Pharma Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 133. Corden Pharma Recent Development
Table 134. Concordia International Company Details
Table 135. Concordia International Business Overview
Table 136. Concordia International Malignant Mesothelioma Drugs Product
Table 137. Concordia International Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 138. Concordia International Recent Development
Table 139. Kyowa Hakko Kirin Company Details
Table 140. Kyowa Hakko Kirin Business Overview
Table 141. Kyowa Hakko Kirin Malignant Mesothelioma Drugs Product
Table 142. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 143. Kyowa Hakko Kirin Recent Development
Table 144. Polaris Pharmaceuticals Company Details
Table 145. Polaris Pharmaceuticals Business Overview
Table 146. Polaris Pharmaceuticals Malignant Mesothelioma Drugs Product
Table 147. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 148. Polaris Pharmaceuticals Recent Development
Table 149. MolMed Company Details
Table 150. MolMed Business Overview
Table 151. MolMed Malignant Mesothelioma Drugs Product
Table 152. MolMed Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 153. MolMed Recent Development
Table 154. Ono Pharmaceutical Company Details
Table 155. Ono Pharmaceutical Business Overview
Table 156. Ono Pharmaceutical Malignant Mesothelioma Drugs Product
Table 157. Ono Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 158. Ono Pharmaceutical Recent Development
Table 159. Nichi-Iko Pharmaceutical Company Details
Table 160. Nichi-Iko Pharmaceutical Business Overview
Table 161. Nichi-Iko Pharmaceutical Malignant Mesothelioma Drugs Product
Table 162. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Drugs Business (2016-2021) & (US$ Million)
Table 163. Nichi-Iko Pharmaceutical Recent Development
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Mesothelioma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Pemetrexed Features
Figure 3. Cisplatin Features
Figure 4. Carboplatin Features
Figure 5. Gemcitabine Features
Figure 6. Vinorelbine Features
Figure 7. Other Features
Figure 8. Global Malignant Mesothelioma Drugs Market Share by Application: 2020 VS 2027
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Oncology Centers Case Studies
Figure 12. Other Case Studies
Figure 13. Malignant Mesothelioma Drugs Report Years Considered
Figure 14. Global Malignant Mesothelioma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Malignant Mesothelioma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Malignant Mesothelioma Drugs Market Share by Regions: 2020 VS 2027
Figure 17. Global Malignant Mesothelioma Drugs Market Share by Regions (2022-2027)
Figure 18. Global Malignant Mesothelioma Drugs Market Share by Players in 2020
Figure 19. Global Top Malignant Mesothelioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Mesothelioma Drugs as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Drugs Revenue in 2020
Figure 21. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2016-2021)
Figure 22. Global Malignant Mesothelioma Drugs Revenue Market Share by Type (2022-2027)
Figure 23. North America Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Malignant Mesothelioma Drugs Market Share by Type (2016-2027)
Figure 25. North America Malignant Mesothelioma Drugs Market Share by Application (2016-2027)
Figure 26. North America Malignant Mesothelioma Drugs Market Share by Country (2016-2027)
Figure 27. United States Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Malignant Mesothelioma Drugs Market Share by Type (2016-2027)
Figure 31. Europe Malignant Mesothelioma Drugs Market Share by Application (2016-2027)
Figure 32. Europe Malignant Mesothelioma Drugs Market Share by Country (2016-2027)
Figure 33. Germany Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Malignant Mesothelioma Drugs Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Malignant Mesothelioma Drugs Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Malignant Mesothelioma Drugs Market Share by Region (2016-2027)
Figure 43. China Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Malignant Mesothelioma Drugs Market Share by Type (2016-2027)
Figure 51. Latin America Malignant Mesothelioma Drugs Market Share by Application (2016-2027)
Figure 52. Latin America Malignant Mesothelioma Drugs Market Share by Country (2016-2027)
Figure 53. Mexico Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Malignant Mesothelioma Drugs Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Malignant Mesothelioma Drugs Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Malignant Mesothelioma Drugs Market Share by Country (2016-2027)
Figure 59. Turkey Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Malignant Mesothelioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. AstraZeneca Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 66. Novartis Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 68. Sanofi Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 69. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 70. Teva Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 71. Boehringer Ingelheim GmbH Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 72. Mylan Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 73. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 74. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 75. Corden Pharma Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 76. Concordia International Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 77. Kyowa Hakko Kirin Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 78. Polaris Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 79. MolMed Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 80. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 81. Nichi-Iko Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Drugs Business (2016-2021)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
世界の悪性中皮腫市場規模・現状・予測（2021年-2027年） Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the foreca…- 世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…
- 世界の悪性黒色腫治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Malignant Melanoma Drugs Market The global Malignant Melanoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
- 世界の悪性神経膠腫市場規模・現状・予測（2021年-2027年） Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and p…